Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
PHASE2
The primary scientific question of interest of this study is whether the co...
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
PHASE2
This study was conducted to evaluate the preliminary effectiveness and safe...
Status
Completed
Location
The First Affiliated Hospital of Wannan Medical College
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
PHASE3
The purpose of this study was to evaluate the safety and efficacy of ociper...
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
PHASE1
The primary purpose of this study is to assess the safety and tolerability ...
Status
Completed
Location
Beijing Friendship Hospital, Capital Medical University
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
PHASE2
This study tested how well and how safely the drug tislelizumab, given eith...